$BBNX News

William Blair Initiates Coverage On Beta Bionics with Market Perform Rating

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Beta Bionics, Inc. (BBNX) Q2 2026 Earnings Call Transcript

Beta Bionics (NASDAQ:BBNX) Q2: EPS Beat and Margin Progress Lift Shares 3% After Hours

Beta Bionics Affirms FY2026 Sales Guidance of $131.000M-$136.000M vs $133.305M Est

Beta Bionics Q2 EPS $(0.53) Beats $(0.56) Estimate, Sales $32.013M Beat $31.443M Estimate

Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $19

Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $22

Beta Bionics: Some Stabilization In Sight

Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website

Beta Bionics Announces Near Real-Time Real-World Data On iLet Bionic Pancreas Is Now Publicly Available At betabionics.com/hcp/real-world-data

Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $17

Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development

Beta Bionics Intends To Fully Commercialize Mint By Q2 2027

B of A Securities Maintains Neutral on Beta Bionics, Lowers Price Target to $11

Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans

Beta Bionics, Inc. (BBNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation

Beta Bionics to Present at the Bank of America Securities Health Care Conference